IGF-1 LR3 Peptide: Research Overview, Purity Data and Where to Buy

IGF-1 LR3 is a recombinant analog of human insulin-like growth factor 1 — an 83-amino-acid polypeptide carrying an arginine-for-glutamic-acid substitution at position 3 and a 13-residue N-terminal extension. Produced in microbial expression systems, it is used in laboratory research examining growth signaling, IGF binding protein interactions, tissue and organ growth, and metabolic regulation in preclinical models.

What IGF-1 LR3 Is and Where It Came From

Native insulin-like growth factor 1 is a 70-amino-acid peptide hormone, structurally related to proinsulin, that mediates much of the downstream anabolic signaling attributed to growth hormone. In circulation, the overwhelming majority of native IGF-1 is bound to a family of six IGF binding proteins (IGFBPs), which regulate its half-life, tissue distribution, and receptor availability. That binding is not incidental — it is the principal brake on IGF-1 activity in vivo.

IGF-1 LR3, commonly written as Long R3 IGF-1, was engineered specifically to sidestep that brake. Two modifications distinguish it from the native molecule. First, the glutamic acid at position 3 is replaced with arginine, a change that markedly weakens IGFBP affinity. Second, a 13-amino-acid extension peptide is fused to the N-terminus, bringing the total length to 83 residues and further reducing binding protein association while improving expression yield and stability in recombinant systems.

The analog emerged from cell-culture science rather than clinical medicine. Long R3 IGF-1 became a widely adopted supplement in serum-free and low-serum mammalian cell culture media, where its resistance to IGFBPs secreted by cultured cells made it substantially more potent than native IGF-1 at equivalent concentrations. That industrial and academic use — supporting CHO cell productivity, hybridoma growth, and stem cell maintenance — remains one of its most established applications. Work published in Applied Microbiology and Biotechnology in 2023 describes recombinant expression of both IGF-1 and LR3 IGF-1 as xylanase fusion constructs in Pichia pastoris, reflecting continued interest in improving how the analog is manufactured at scale.

Reported Mechanism of Action

The mechanistic account of IGF-1 LR3 is straightforward in outline and considerably more nuanced in detail.

Receptor engagement

Like native IGF-1, the analog is understood to bind the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase. Receptor autophosphorylation recruits insulin receptor substrate proteins and Shc, initiating two principal downstream cascades: the PI3K/Akt/mTOR axis, associated in the literature with protein synthesis, cell survival, and substrate uptake; and the Ras/Raf/MAPK axis, associated with proliferation and differentiation signaling. IGF-1R shares substantial homology with the insulin receptor, and cross-reactivity at higher concentrations is a recurring theme in the metabolic literature.

The binding protein story

The defining feature of IGF-1 LR3 is not receptor affinity — reported affinity for IGF-1R is generally described as somewhat lower than native IGF-1 — but rather its reduced sequestration by IGFBPs. With less of the administered analog captured into binary and ternary complexes, a larger free fraction is available to reach receptors, and clearance dynamics differ from those of the native peptide. This is the mechanistic reason the analog behaves as a more persistent signal in culture and in animal models.

Systemic feedback

Free IGF signaling does not occur in isolation. A 1995 study in The Journal of Endocrinology reported that Long R3 IGF-I infusion in guinea pigs stimulated organ growth while simultaneously reducing plasma concentrations of IGF-I, IGF-II, and IGF binding proteins. That combination — local growth effects alongside suppression of the endogenous IGF axis — is a useful reminder that the analog perturbs a regulated system rather than simply adding to it.

What the Research Literature Examines

Published work on IGF-1 LR3 clusters into several distinct areas. Across all of them, evidence remains preliminary, and results are notably mixed.

Fetal and developmental physiology

Fetal sheep models represent one of the more active areas. A 2025 paper in the American Journal of Physiology — Endocrinology and Metabolism reported that IGF-1 LR3 did not promote growth in late-gestation growth-restricted fetal sheep, a negative finding that tempers assumptions about the analog's anabolic reach in compromised developmental contexts. Related work published in the Journal of Developmental Origins of Health and Disease in 2023 examined glucose-stimulated insulin secretion during acute IGF-1 LR3 infusion into fetal sheep and reported that the observed attenuation did not persist in isolated islets — suggesting the effect on insulin secretion may be systemic or contextual rather than intrinsic to the beta cell.

Metabolic and glucose regulation

Because of structural homology with insulin and shared downstream signaling, effects on glucose handling recur throughout the IGF literature. The fetal sheep work above is one example; broader preclinical interest concerns how IGFBP-independent signaling alters glucose disposal and endogenous hormone secretion. This remains an area where mechanism is better characterized than outcome.

Organ and tissue growth

The guinea pig infusion work cited above sits in a small-animal literature examining differential organ growth responses to IGF analogs. Notably, that study reported organ-level growth alongside reduced circulating IGF and IGFBP concentrations, illustrating that whole-body and tissue-level readouts can diverge.

Neurobiology

A 2025 study in the Journal of Alzheimer's Disease examined intranasal Long R3 IGF-1 in male 5XFAD mice and reported amyloid plaque remodeling in cerebral cortex without preservation of cognitive function. It is a representative example of how histological change and functional outcome can dissociate in rodent models, and why the field treats such findings as hypothesis-generating rather than conclusive.

Bioprocess and expression science

Separate from biology, a body of work addresses how the analog is produced — yeast and bacterial expression systems, fusion partners, refolding, and purification. The 2023 Pichia pastoris xylanase fusion work falls here. This literature matters to researchers because expression route influences the impurity profile that analytical testing is designed to detect.

Laboratory Handling in General Terms

IGF-1 LR3 is supplied as a lyophilized powder because polypeptides of this size are considerably more stable dry than in solution. General handling principles apply broadly across recombinant growth factors.

Reconstitution practice

Standard laboratory practice calls for allowing the sealed vial to equilibrate to ambient temperature before opening, introducing diluent slowly down the vial wall rather than directly onto the lyophilized cake, and permitting the material to dissolve without vigorous shaking. Peptides of this class are sensitive to shear and to air-liquid interface stress, both of which can drive aggregation. Gentle swirling or inversion is preferred over vortexing. Some laboratories use mildly acidic diluent for initial solubilization before dilution into working buffer; the appropriate choice depends on the assay and downstream compatibility.

Storage

Lyophilized material is typically held frozen and protected from light and moisture, with short-term refrigeration acceptable for material in active use. Once in solution, stability declines meaningfully, and the standard mitigation is aliquoting into single-use volumes at the time of reconstitution so that repeated freeze-thaw cycles are avoided. Each cycle introduces opportunity for aggregation and loss of biological activity. Documenting reconstitution date, diluent, and concentration on every aliquot is basic traceability hygiene and prevents avoidable ambiguity when results are later interpreted. Detailed procedural guides sit in the supporting articles beneath this hub.

Regulatory and Research-Use Status

IGF-1 LR3 is not an FDA-approved drug for any of the applications discussed on this page. It has not been authorized as a therapeutic product, and it is not a dietary supplement. Material of this type is supplied for laboratory research use only, to qualified researchers and institutions, and is not intended for human or veterinary use, diagnostic use, or incorporation into any consumer product.

Beyond drug regulation, IGF-1 and its analogs appear on the World Anti-Doping Agency Prohibited List under the peptide hormones and growth factors category, and sporting bodies test for them. Import, possession, and distribution rules vary by jurisdiction, and researchers are responsible for confirming the requirements applicable to their institution and location. Institutional oversight — IACUC review for animal work, biosafety committee approval where relevant — applies independently of how a compound is classified commercially.

How Researchers Evaluate Supplier Quality

Because IGF-1 LR3 is a recombinant protein rather than a short synthetic peptide, its impurity profile is more complex: truncated species, misfolded isoforms, host cell protein carryover, and aggregates are all plausible. Analytical documentation is what separates a characterized reagent from an unknown.

• Batch-specific third-party COA. The certificate should correspond to the exact lot in hand, be dated, and originate from an independent laboratory rather than being self-reported. A generic or undated COA reused across lots is a meaningful warning sign.
• HPLC purity. Reversed-phase HPLC quantifies purity and reveals related-substance peaks. The chromatogram itself is more informative than a single headline percentage, since peak shape and impurity distribution carry information a number does not.
• Mass spectrometry identity. Because the analog differs from native IGF-1 by a defined substitution and an N-terminal extension, observed mass should match the calculated mass for the 83-residue construct. Mass spec is the primary defense against substitution or mislabeling.
• Batch traceability. A lot number that links vial, COA, and production record allows results to be tied to specific material — essential when experiments are repeated months apart or replicated across sites.
• Presentation and consistency. Uniform fill, intact lyophilized cake appearance, seal integrity, and consistent labeling across shipments are practical proxies for process control.

Some laboratories add functional confirmation — a receptor phosphorylation or cell proliferation readout — since analytical purity does not by itself establish that a protein is correctly folded and bioactive.

Where the Open Questions Are

The honest summary is that IGF-1 LR3 is well characterized as a reagent and thinly characterized as a biological intervention. Several gaps stand out.

1. Effect direction is context-dependent. The fetal sheep growth-restriction work reporting no growth promotion sits uneasily beside guinea pig data reporting organ growth. Understanding which physiological contexts produce which response is unresolved.
2. Systemic feedback is under-mapped. Suppression of endogenous IGF-I, IGF-II, and binding proteins during infusion raises questions about net signaling that single-endpoint studies rarely address.
3. Structural change without functional change. The 5XFAD finding of plaque remodeling without cognitive preservation exemplifies a broader problem: which biomarkers, if any, track meaningful outcomes.
4. Metabolic crosstalk. The extent of insulin receptor engagement and its consequences for glucose regulation across models remains incompletely defined.
5. Human data are absent. There is no controlled clinical literature supporting the performance or body-composition uses often discussed informally, and this page makes no claims about them.

For researchers building a protocol, that combination — a clear mechanism, a modest and mixed evidence base, and rigorous material characterization — is the realistic starting point.

Research-grade IGF-1 LR3: Real Peptides supplies IGF-1 LR3 for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore IGF-1 LR3 research on Real Peptides

The articles below go deeper on the questions researchers ask most about IGF-1 LR3.

Buying & quality

• IGF-1 LR3 Reddit Reviews Community — Real User Insights
• IGF-1 LR3 Cost Per Month Budget — Real Pricing Breakdown

Reconstitution, storage & handling

• How Long IGF-1 LR3 Vial Lasts? (Storage & Usage) | Real…
• IGF-1 LR3 Storage: Does It Really Need the Fridge?

Stacks & comparisons

• IGF 1 LR3 Stacks: Our Expert Research & Recommendations
• Stacking IGF-1 LR3 Follistatin-344 Muscle Research
• IGF-1 LR3 Real vs Fake: How to Tell — Real Peptides
• Follistatin-344 vs IGF-1 LR3 — Research Comparison

Legal & regulatory

• Is IGF-1 LR3 Legal? (Regulatory Status Explained)
• Is IGF-1 LR3 Legal in 2026? (Current Regulatory Status)

Research timelines & mechanisms

• How Long IGF-1 LR3 Stays in System — Clearance Timeline

Safety & side effects

• IGF-1 LR3 with Alcohol Safety — Risks and Protocols
• IGF-1 LR3 with Coffee Safety — Interaction Risks Explained

Research questions

• Does IGF-1 LR3 Increase Testosterone? A Deep Dive Into The Science
• Does IGF-1 LR3 Increase Testosterone? The Unflinching Answer
• IGF-1 LR3: Laboratory Handling, Storage and Stability
• IGF-1 LR3 Needles Syringes — Equipment Guide | Real Peptides

Ordering IGF-1 LR3 for research

Real Peptides supplies IGF-1 LR3 as a research-use-only reference material: lyophilized powder in a sealed vial, labeled with the lot number that matches its published certificate of analysis. Every batch is tested by an independent laboratory before it ships, and the certificate is published before purchase, so a researcher can read the purity result for the exact lot they are ordering.

• Product page: IGF-1 LR3 for research, with the vial formats currently stocked and the certificate for the batch shipping now.
• Certificates: search any lot number at the certificate lookup; reports stay on file after a batch sells out.
• Shipping: orders dispatch within 24 hours on business days from inventory in Florida and California to every US state; see research peptides by location.
• Related compounds: browse the full research peptide catalog.

Nothing on this page is medical advice or guidance on administering any compound. IGF-1 LR3 is not for human or animal use, and buyers confirm they are 21 or older and purchasing for laboratory research.

How IGF-1 LR3 differs from follistatin-pathway compounds

IGF-1 LR3 acts on the IGF-1 receptor. Follistatin-pathway compounds work upstream, by binding myostatin and activin. Researchers comparing the two often also ask about FLGR-242, a vendor-marketed follistatin analog with no published human trials.

How does IGF-1 LR3 differ from native IGF-1 and other IGF-1 analogs?

IGF-1 LR3 is a recombinant analog of human insulin-like growth factor 1 carrying two structural changes: a substitution at position 3 (glutamic acid replaced by arginine) and a 13-amino-acid extension on the N-terminus, giving an 83-residue chain instead of the native 70. Both modifications were introduced to reduce affinity for the insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6) that normally sequester circulating IGF-1. Because most native IGF-1 is bound in ternary complexes with IGFBP-3 and the acid-labile subunit, free analog concentrations behave differently in buffer and serum-containing systems, which is one reason the two molecules are not interchangeable in assay design. Receptor engagement itself is still directed at IGF-1R, as outlined in the discussion of the IGF-1 receptor mechanism. Related analogs such as DES(1-3)IGF-1 use a different strategy — deletion of the first three residues — to achieve a comparable reduction in binding-protein affinity. Side-by-side summaries appear in the research peptide comparison and in the overview of IGF-1 LR3 alternatives. The engineering rationale and the sequence of patents and publications behind it are covered in the development history.

Why is IGF-1 LR3 described as having an extended half-life?

The phrase "extended half-life" refers to observations in preclinical model systems rather than any approved human pharmacokinetic label. Native IGF-1 in circulation is largely bound to IGFBP-3 and the acid-labile subunit, a complex that both protects it from clearance and restricts receptor access. Reduced binding-protein affinity in the LR3 analog changes that balance: more of the molecule remains unbound, which alters distribution and the kinetics measured in animal plasma. Published work on IGF analogs generally reports longer apparent persistence for binding-protein-resistant forms, though reported values differ substantially with species, assay antibody, and sampling design, so researchers usually treat any single number with caution. A fuller treatment of the pharmacokinetic literature is collected under extended half-life, while the variables that influence recovery and transport in experimental systems are described in bioavailability and delivery factors. Half-life in solution is a separate question from half-life in a biological matrix — peptide integrity in stored material depends on temperature, buffer, and handling, topics addressed in laboratory handling. Signaling duration downstream of receptor occupancy is discussed in downstream cellular and metabolic effects.

What do animal studies report about IGF-1 LR3 and skeletal muscle?

Most of the published record on long-R3-IGF-1 comes from rodent and livestock work conducted since the early 1990s, alongside a broad literature on native IGF-1 in muscle. Investigators have examined endpoints such as muscle wet weight, fiber cross-sectional area, myonuclear number, protein synthesis rates, and markers of satellite cell activity. Findings vary with species, age, nutritional state, and whether the model includes a catabolic or disuse challenge, so results in one system do not transfer cleanly to another. Study designs, model choices, and common endpoints are catalogued in animal research mechanisms and study protocols. A recurring methodological problem is that growth-factor responses in rodents are often larger and faster than anything documented in larger mammals, a translation gap examined in animal versus human research. At the tissue level, the proposed pathway runs through IGF-1R, PI3K/Akt, and mTOR signaling, as summarized in muscle growth mechanism research, with a separate body of work on quiescent satellite cell recruitment described under satellite cell activation. None of this material supports human conclusions.

What analytical methods verify IGF-1 LR3 identity and purity?

Identity and purity for a recombinant 83-residue peptide are normally established with a combination of techniques rather than a single test. Reversed-phase HPLC separates the target from truncated, oxidized, or deamidated species and produces the percentage purity figure that appears on most certificates of analysis. Mass spectrometry — typically ESI-MS or MALDI-TOF — confirms the intact molecular mass against the theoretical value for the LR3 sequence, which distinguishes it from native IGF-1 or DES(1-3)IGF-1 by a clear mass difference. Supporting assays may include SDS-PAGE or size-exclusion chromatography for aggregates and dimers, Karl Fischer or loss-on-drying for residual moisture, and endotoxin testing for material intended for cell culture. A COA is most useful when it is batch-specific, dated, attributed to a named laboratory, and accompanied by the raw chromatogram and spectrum rather than a summary table. Guidance on reading these documents appears in the buying guide for researchers and in the checklist on how to tell if a peptide supplier is legitimate. Storage conditions for lyophilized material and the documentation that should accompany it are covered in laboratory handling and the general IGF-1 LR3 FAQ.

How is IGF-1 LR3 used in in vitro cell-culture research?

In cell culture, the practical appeal of the LR3 analog is that serum and cell-secreted binding proteins interfere less with receptor access than they do with native IGF-1, which makes exposure conditions easier to reproduce across plates and passages. It has been used as a supplement in serum-reduced and serum-free media systems, in myoblast and myotube differentiation models, and in proliferation assays for several adherent cell lines. Typical readouts include BrdU or EdU incorporation, MTT or resazurin viability signals, phospho-Akt and phospho-ERK immunoblots, and transcript panels for myogenic regulatory factors. Culture-specific considerations such as carrier protein choice, adsorption to plasticware, and media exchange intervals affect measured activity and are discussed in in vitro research. Work focused specifically on division rates and population expansion is summarized under cell proliferation, while transcriptional endpoints are collected in gene expression and molecular mechanisms. Because sustained mitogenic signaling is central to the molecule's behavior, cultured systems are also where questions about cell number versus cell size are most tractable, a theme explored in hyperplasia and cellular growth research.

Which biomarkers do IGF-axis research programs track?

Research programs built around the IGF axis generally monitor more than a single analyte, because total IGF-1 alone is a poor description of what is happening biologically. Commonly tracked measures in preclinical and observational work include total and free IGF-1, IGFBP-3, IGFBP-1, the acid-labile subunit, the IGF-1 to IGFBP-3 molar ratio, growth hormone, and glucose and insulin parameters because of the metabolic overlap between IGF-1R and insulin receptor signaling. An important analytical caveat is that many commercial IGF-1 immunoassays are raised against native human IGF-1 and may under-recover or cross-react unpredictably with the LR3 analog, which complicates interpretation of any single reported value. The panel most often referenced in the literature is described in biomarkers researchers track, with assay-selection notes in laboratory markers checked before and after. Background on what elevation of circulating IGF-1 does and does not indicate appears in IGF-1 elevation research. Longitudinal datasets are sparse, and the limits of extended-duration observation are reviewed in long-term studies. None of these measurements constitute clinical monitoring guidance.

Does IGF-1 LR3 activate the insulin receptor as well as IGF-1R?

IGF-1 and insulin receptors are structurally homologous tyrosine kinase receptors, and cells commonly express IGF-1R/IR hybrid receptors in addition to each homodimer. Native IGF-1 binds the insulin receptor with low affinity — orders of magnitude weaker than insulin — but at sufficient free concentrations this cross-reactivity becomes measurable, and hybrid receptors add further complexity because their ligand preference depends on the subunit composition in a given tissue. This is the mechanistic basis for the hypoglycemia observed in animal and clinical studies of IGF-1 preparations generally, and it is the reason glucose-related endpoints appear so frequently in IGF research designs. Receptor-level selectivity and the evidence behind it are discussed in IGF-1 receptor agonism, while the recognized hazard categories in preclinical work — including metabolic effects and the mitogenicity concerns that accompany any sustained growth-factor signal — are set out in contraindications and safety risks. Post-receptor branching through PI3K/Akt toward both metabolic and growth outputs is described in downstream effects, and the overlap between these two arms underlies the adipose-tissue questions raised in fat loss research.

Is IGF-1 LR3 prohibited under anti-doping regulations?

Yes. The World Anti-Doping Agency's Prohibited List includes growth hormone, insulin-like growth factor 1 and its analogs and mimetics under the peptide hormones and growth factors category, and this prohibition applies both in and out of competition. Most national anti-doping organizations and major sporting federations adopt the WADA list directly, so the classification carries across jurisdictions. Detection work has focused on immunoassay and LC-MS/MS approaches capable of distinguishing analogs from endogenous IGF-1 by mass and sequence, which is one practical consequence of the LR3 molecule's 13-residue extension. The broader literature on growth factors in sport-science contexts, and the limits of extrapolating animal data to athletic questions, is reviewed in athletic performance research insights. Anti-doping prohibition is a separate matter from national drug law and from approval status, distinctions explained in legal and regulatory status and in the summary of FDA approval status. Current jurisdictional detail is tracked in legal status for 2026. Material sold for laboratory research is supplied for in vitro and preclinical investigation only and is not intended for human consumption in any setting.

Has IGF-1 LR3 been evaluated in human clinical trials?

There is no approved human product containing long-R3-IGF-1, and the published clinical literature on this specific analog is essentially absent. What does exist is a substantial human research record for recombinant native IGF-1 (mecasermin) and for the IGF-1/IGFBP-3 complex, studied in severe primary IGF-1 deficiency, growth hormone insensitivity, diabetes, amyotrophic lateral sclerosis, and burn and catabolic states. Those trials established that IGF-1 signaling can be manipulated in humans and identified the recurring safety themes — hypoglycemia, tissue overgrowth, and theoretical mitogenicity — but they used a different molecule with different binding-protein behavior, so conclusions do not transfer directly. The LR3 analog's own record consists mainly of cell-culture applications, veterinary and livestock studies, and its long-standing commercial role as a serum-free media supplement in biomanufacturing. The state of registered and published trial activity is tracked in clinical trials, and the methodological reasons the evidence base remains thin are set out in comparative studies and evidence review and in animal versus human research. Gaps in extended-duration data are discussed in long-term studies.

References

Peer-reviewed sources on IGF-1 LR3 indexed in PubMed, listed for research context. Real Peptides supplies IGF-1 LR3 for laboratory research use only.

1. IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. American journal of physiology. Endocrinology and metabolism, 2025. PMID 39679943. doi:10.1152/ajpendo.00259.2024
2. Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice. Journal of Alzheimer's disease : JAD, 2025. PMID 39610283. doi:10.1177/13872877241299056
3. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied microbiology and biotechnology, 2023. PMID 37261455. doi:10.1007/s00253-023-12606-0
4. Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. Journal of developmental origins of health and disease, 2023. PMID 37114757. doi:10.1017/S2040174423000090
5. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. The Journal of endocrinology, 1995. PMID 7561636. doi:10.1677/joe.0.1460247